Browsing: Secondary Life Markets
Longevity and Mortality Investor’s coverage of the secondary life markets, including life settlements, equity release, reverse mortgages and life contingent structured settlements
Cashing Out has been shortlisted for the Best Documentary Short Film at the 98th annual Academy Awards.
Two new reports from insurance asset manager Conning – one of them produced in conjunction with life settlement industry group the European Life Settlement Association (ELSA), publisher of Longevity and Mortality Investor – paint an optimistic picture of the state of the life settlement market.
Life Settlement Investor Sentiment 2025 is a new report published by insurance asset management firm Conning, in conjunction with ELSA.
Charles H. Portz, IV joins Lighthouse Life as CFO; Adam Lippman and Noam Weiss promoted to Chief Operating Officer and Chief Business Officer, respectively.
New study finds that while the number of new policy settlements declined in 2024, long-term growth drivers remain strong.
Changes to the NCOIL life settlement model act in the past 25 years have been beneficial to the life settlement market but educating consumers, policyholders and investors remains the rising tide that will lift all boats.
Within the life settlement industry, the medical record review has long remained one of the most resource-intensive and time-consuming stages of the process but recent advancements in automation and artificial intelligence, however, are beginning to change this dynamic.
Litigation risk in the life settlement market takes multiple forms, from cost of insurance increases to estate challenges, from credit risk to stranger-owned life insurance cases. Liam Bodemeaid, Actuarial Consultant at Actuarial Risk Management, introduces a new framework to price litigation risk with a little bit more logic, data, and structure in a guest article.
Despite its growth and maturity in the past 25 years, the life settlement asset class remains a complicated one that requires deep analysis so that investors can understand it fully.
Under optimistic scenarios, new research from Swiss Re projects that GLP-1 medications could reduce all-cause mortality in the US by as much as 6.4% by 2045. But what will the impact be on the life settlement market?